New Horizon Health (FRA:6YZ) Research & Development: €16.9 Mil (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6YZ New Horizon Health Ltd FRA:6YZ
35 GF Score
Price €1.62
View Full Analysis

What is New Horizon Health Research & Development?

New Horizon Health FRA:6YZ 35 Research & Development is €16.9 Mil as of Jun. 2023. GuruFocus rates FRA:6YZ with a GF Score™ of 35/100.

Research & Development is the aggregate amount of research and development expenses during the year. New Horizon Health's Research & Development for the six months ended in Jun. 2023 was €9.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was €16.9 Mil.

New Horizon Health  (FRA:6YZ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

New Horizon Health Research & Development Related Terms

New Horizon Health Research & Development Historical Data

* Premium members only.

The historical data trend for New Horizon Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

New Horizon Health Research & Development Chart

New Horizon Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
1.89 3.38 3.19 8.18 12.81

New Horizon Health Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only 2.74 5.23 5.78 7.27 9.64
FRA:6YZ
35GF Score
New Horizon Health Ltd FRA:6YZ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

New Horizon Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €16.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €16.9 Mil mean?
New Horizon Health (FRA:6YZ) has a Research & Development of €16.9 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on New Horizon Health and its competitors.
Is New Horizon Health's Research & Development too high?
New Horizon Health's current Research & Development is €16.9 Mil. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's Research & Development compare to ABT and SYK?
New Horizon Health's Research & Development of €16.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on New Horizon Health and its competitors. New Horizon Health's current Research & Development is €16.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (FRA:6YZ) has a current Research & Development of €16.9 Mil. The current Research & Development is €16.9 Mil. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For New Horizon Health (FRA:6YZ), the current Research & Development is €16.9 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

New Horizon Health Business Description

Address 400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score

Get the complete analysis for FRA:6YZ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price